Log in

Relevant bibliographies by topics / Breast cancer treatment][Cancer

Contents

Journal articles
Dissertations / Theses
Books
Book chapters
Conference papers
Reports

Academic literature on the topic 'Breast cancer treatment][Cancer'

Author: Grafiati

Published: 4 June 2021

Last updated: 11 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Breast cancer treatment][Cancer.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Breast cancer treatment][Cancer"

1

Capelo Medina, E., J. Muñoz García, J. Quirós Rivero, M. Ropero Carmona, Y. Ríos Kavadoy, A. Corbacho Campos, A. Torres García, and J. Cabrera Rodríguez. "Second cancers after breast cancer treatment." Reports of Practical Oncology & Radiotherapy 18 (June 2013): S183. http://dx.doi.org/10.1016/j.rpor.2013.03.112.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Matesich, Sister Mary Andrew, and Charles L. Shapiro. "Second cancers after breast cancer treatment." Seminars in Oncology 30, no. 6 (December 2003): 740–48. http://dx.doi.org/10.1053/j.seminoncol.2003.08.022.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Miller, Elizabeth, Hee Jin Lee, Amriti Lulla, Liz Hernandez, Prashanth Gokare, and Bora Lim. "Current treatment of early breast cancer: adjuvant and neoadjuvant therapy." F1000Research 3 (August 19, 2014): 198. http://dx.doi.org/10.12688/f1000research.4340.1.

Full text

Abstract:

Breast cancer is the most commonly diagnosed cancer in women. The latest world cancer statistics calculated by the International Agency for Research on Cancer (IARC) revealed that 1,677,000 women were diagnosed with breast cancer in 2012 and 577,000 died. The TNM classification of malignant tumor (TNM) is the most commonly used staging system for breast cancer. Breast cancer is a group of very heterogeneous diseases. The molecular subtype of breast cancer carries important predictive and prognostic values, and thus has been incorporated in the basic initial process of breast cancer assessment/diagnosis. Molecular subtypes of breast cancers are divided into human epidermal growth factor receptor 2 positive (HER2 +), hormone receptor positive (estrogen or progesterone +), both positive, and triple negative breast cancer. By virtue of early detection via mammogram, the majority of breast cancers in developed parts of world are diagnosed in the early stage of the disease. Early stage breast cancers can be completely resected by surgery. Over time however, the disease may come back even after complete resection, which has prompted the development of an adjuvant therapy. Surgery followed by adjuvant treatment has been the gold standard for breast cancer treatment for a long time. More recently, neoadjuvant treatment has been recognized as an important strategy in biomarker and target evaluation. It is clinically indicated for patients with large tumor size, high nodal involvement, an inflammatory component, or for those wish to preserve remnant breast tissue. Here we review the most up to date conventional and developing treatments for different subtypes of early stage breast cancer.

APA, Harvard, Vancouver, ISO, and other styles

4

Jung, Hong Kyu, Jihyoun Lee, Zisun Kim, Min Hyuk Lee, and Ilkyun Lee. "Development of second primary cancers in breast cancer survivors." Journal of Clinical Oncology 34, no. 3_suppl (January 20, 2016): 257. http://dx.doi.org/10.1200/jco.2016.34.3_suppl.257.

Full text

Abstract:

257 Background: Breast cancer survivors have slightly increased risk of second primary cancers. Importance of screening for second cancers has been raised due to increased survival in those populations. Not only having genetic risk such as BRCA mutation, but also treatment-related risk presents. The most common second primary cancer is breast cancer. Colon cancer, uterine cancer, and ovarian cancer showed increased cumulative incidence. In this study, we assessed development second primary cancers in breast cancer survivors. Methods: Medical record of breast cancer patients was reviewed retrospectively in three tertiary medical institutions. Available data of ICD-9 record after breast cancer diagnosis was evaluated. Diagnosis of second primary breast cancer was excluded in evaluation. Results: Since Jan 1989 to Jan 2014, available medical records were reviewed in breast cancer patients(N = 5880) in three institutions(one urban and the other two rural institutions). Cumulative incidence of overall second primary cancers was 4.57%. Among 269 second primary cancers, thyroid cancer(44.2%) was most common second primary cancer, followed by gastric cancer(10.0%). Gastric cancers were more common in rural institution than urban area(14.2 % vs 5.5%), while incidence of thyroid cancer is elevated in urban institution(57.8% vs 31.9%). Among 9 patients who has been diagnosed endometrial cancer, 7 patients had history of selective estrogen receptor modulator(tamoxifen or toremifen) treatment. Development of lung cancer was not related to breast cancer radiation treatment(4 of 15 patients). Leukemia after breast cancer treatment was diagnosed in 5 patients (8.5% of second primary cancers), three of them were adult T cell leukemia and two of them were acute myeloid leukemia. Conclusions: Incidence of cancer in general population was reflected to development of second primary cancer in breast cancer survivors. Endocrine treatment was related increased incidence of endometrial cancer, respectively. Application of personalized cancer screening plan would be important in this patient group.

APA, Harvard, Vancouver, ISO, and other styles

5

Young-Afat, Danny A., Carla H. van Gils, David J. Bruinvels, Carmen C. van der Pol, Arjen J. Witkamp, Sieta Sijtsema, Yvette Jonasse, et al. "Patients’ and Health Care Providers’ Opinions on a Supportive Health App During Breast Cancer Treatment: A Qualitative Evaluation." JMIR Cancer 2, no. 1 (June 7, 2016): e8. http://dx.doi.org/10.2196/cancer.5334.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Sarkar, Esha, Aparna Misra, Rumana Ahmad, and Abbas Ali Mahdi. "CURCUMA LONGA: THE GOLDEN SPICE, POWERFULANTICANCER AGENT IN BREAST CANCER TREATMENT." Era's Journal of Medical Research 6, no. 2 (December 2019): 124–30. http://dx.doi.org/10.24041/ejmr2019.142.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Bhushan, Arya, Andrea Gonsalves, and Jyothi U. Menon. "Current State of Breast Cancer Diagnosis, Treatment, and Theranostics." Pharmaceutics 13, no. 5 (May 14, 2021): 723. http://dx.doi.org/10.3390/pharmaceutics13050723.

Full text

Abstract:

Breast cancer is one of the leading causes of cancer-related morbidity and mortality in women worldwide. Early diagnosis and effective treatment of all types of cancers are crucial for a positive prognosis. Patients with small tumor sizes at the time of their diagnosis have a significantly higher survival rate and a significantly reduced probability of the cancer being fatal. Therefore, many novel technologies are being developed for early detection of primary tumors, as well as distant metastases and recurrent disease, for effective breast cancer management. Theranostics has emerged as a new paradigm for the simultaneous diagnosis, imaging, and treatment of cancers. It has the potential to provide timely and improved patient care via personalized therapy. In nanotheranostics, cell-specific targeting moieties, imaging agents, and therapeutic agents can be embedded within a single formulation for effective treatment. In this review, we will highlight the different diagnosis techniques and treatment strategies for breast cancer management and explore recent advances in breast cancer theranostics. Our main focus will be to summarize recent trends and technologies in breast cancer diagnosis and treatment as reported in recent research papers and patents and discuss future perspectives for effective breast cancer therapy.

APA, Harvard, Vancouver, ISO, and other styles

8

Fentiman, Ian S. "Breast cancer treatment." British Journal of Nursing 4, no. 8 (April 27, 1995): 431–39. http://dx.doi.org/10.12968/bjon.1995.4.8.431.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Suwankhong, Dusanee, and Pranee Liamputtong. "Breast Cancer Treatment." Cancer Nursing 39, no. 3 (2016): 213–20. http://dx.doi.org/10.1097/ncc.0000000000000255.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Waks, Adrienne G., and Eric P. Winer. "Breast Cancer Treatment." JAMA 321, no. 3 (January 22, 2019): 288. http://dx.doi.org/10.1001/jama.2018.19323.

Full text

APA, Harvard, Vancouver, ISO, and other styles

More sources

Dissertations / Theses on the topic "Breast cancer treatment][Cancer"

1

Li, Pei-Xiang. "Molecular approaches to breast cancer treatment." Thesis, National Library of Canada = Bibliothèque nationale du Canada, 1999. http://www.collectionscanada.ca/obj/s4/f2/dsk1/tape7/PQDD_0023/NQ50092.pdf.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Abraham, J. E. "The pharmacogenetics of breast cancer treatment." Thesis, University of Cambridge, 2011. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.595327.

Full text

Abstract:

The core project in this thesis is the translational study PGSNPS, which aimed to investigate the pharmacogenetics of breast cancer chemotherapy in the adjuvant setting. Blood or saliva samples were collected from over 2300 patients, who were recruited during a 4 year period. The trial design was adapted to a GWAS approach. The combination of high quality genotype data and detailed clinical information allows this collection to be a useful resource not only for pharmacogenetic analysis but for investigation of prognosis and susceptibility in future analyses. I also examined the role of candidate gene analysis in the identification of variants associated with survival and susceptibility analysis. Candidate gene analysis of the prostaglandin pathway investigated the potential role of key genes in this pathway and their association with breast cancer susceptibility and survival. There was little evidence that common variants are associated with modest risks of breast cancers and no evidence for association with overall survival (OS) for any tagSNP studied. The metabolic enzyme cytochrome P450 2D6, (CYP2D6), is involved in the metabolism of tamoxifen to its active metabolites. I examined the role of the CYP2D6 gene in breast cancer specific survival (BCSS) and OS in tamoxifen treated breast cancer patients. One putative poor metaboliser (PM) CYP2D6*6 may be associated with decreased BCSS and OS, but the prior probability of such an association is low. All other putative functional variants showed no association. The evidence from this study does not support implementation of routine CYP2D6 testing pre-treatment to guide choice of hormone therapy.

APA, Harvard, Vancouver, ISO, and other styles

3

Whitman, Birgit. "Breast cancer : patient narratives and treatment methods." Thesis, University of Glasgow, 2004. http://theses.gla.ac.uk/2969/.

Full text

Abstract:

This thesis concentrates on the treatment of women with breast cancer in the 19th and 20th century. It analyses written published patient narratives linking them with clinical developments. Medical history holds a rich source of information providing the view of the clinician. This includes case reports and case series from one surgeon or one hospital for the earlier period of the study and has progressed to the double blind randomised controlled trial that dominates comparative research today. There is an imbalance in the material available for the analysis of patients’ perceptions of their treatment. The patient view is not represented well in the history of medicine. This thesis attempts to provide a more complete assessment of the developments in breast cancer treatment by including the patient’s view. Three narratives provide an insight into the perception of women who were treated with breast cancer prior to the introduction of anaesthesia and infection control. The novelist, Fanny Burney (1752-1840), underwent a mastectomy in 1811. In a letter to her sister she wrote about her experience providing details of her diagnosis and treatment. In comparison, Emily Gosse (1806-1857) refused a mastectomy for her breast cancer and sought alternative treatment with caustics. Her husband, Phillip Gosse and friend, Anna Shipton, wrote narratives about Emily’s suffering. A third narrative provides the view of a woman with breast cancer who received no treatment and died of metastatic breast cancer; Zelie Martin died in 1877. These narratives were linked to a case report by Lorenz Heister (1683-1758). Heister described the procedure for amputation of the breast in detail. His method prevailed until new scientific developments in surgery such as anaesthesia and infection control improved the short-term survival of patients and enabled surgeons to operate sooner with a greater attention to detail.

APA, Harvard, Vancouver, ISO, and other styles

4

Bossaer, John B., and Christian M. Thomas. "Adjuvant Treatment of Newly Diagnosed Breast Cancer." Digital Commons @ East Tennessee State University, 2011. https://dc.etsu.edu/etsu-works/2313.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Keim, Rebecca. "Treatment-Induced Breast Cancer Dormancy and Relapse." VCU Scholars Compass, 2014. http://scholarscompass.vcu.edu/etd/3500.

Full text

Abstract:

When breast tumor cells encounter stress due to cancer therapies, they may enter a dormant state, escaping from treatment-induced apoptosis. Dormant cells may eventually regain proliferative capabilities and cause recurrent metastatic disease, which is the leading cause of mortality in breast cancer patients. We sought to determine if a high dose of radiation therapy (RT) or combined chemo-immunotherapy, with and without the blockade of autophagy by chloroquine (CQ), could overcome treatment-induced tumor dormancy or relapse. We found that autophagy contributes in part to treatment-induced tumor dormancy. We also found that three therapeutic strategies were successful in inhibiting or preventing tumor relapse. These include: 18Gy/day RT, chemotherapy combined with the blockade of autophagy, and combined chemo-immunotherapy. Follow-up studies are needed to determine the feasibility of preventing tumor relapse by prolonging tumor dormancy versus eliminating dormant tumor cells.

APA, Harvard, Vancouver, ISO, and other styles

6

Thanoon, David. "Computational framework for local breast cancer treatment." Thesis, Bordeaux 1, 2011. http://www.theses.fr/2011BOR14387/document.

Full text

Abstract:

Le cancer du sein est le cancer le plus fréquent chez les femmes. Il y a une multitude de solutions proposées concernant une éventuelle intervention médicale pour le cancer du sein ‐ une en particulier est la chirurgie mammaire conservatrice (tumoréctomie). Le but de la tumoréctomie est de parvenir à un contrôle local du cancer, ainsi que de préserver une forme du sein qui satisfait les besoins esthétiques de la femme. Bien que ces objectifs sont généralement atteint, il reste encore parfois des résultats inattendus,tels qu'une tumeur récurrence locale, ou des résultats cosmétiques insuffisants.L'objectif de cette thèse est de proposer une plateforme de calcul, qui contribue à la tumoréctomie. Cela comprend:1) Une étude de la dynamique de croissance des tumeurs du sein.2) Une étude sur la prédiction du contour du sein grâce a la chirurgie virtuelle.3) Un modèle de calcul de la forme finale du sein après cicatrisation
Breast cancer is the most common cancer among women in the developed as well as the developing countries. There are a plethora of proposed solutions regarding possible medical interventions for breast cancer–one in particular is Breast Conserving Therapy (BCT). BCT comprises of complete surgical excision of the tumor (partialmastectomy), and post-operative radiotherapy for the remaining breast tissue. This is a feasible treatment for most women with breast cancer. The goal of BCT is toachieve local control of the cancer, as well as to preserve breast shape that appeases awoman’s cosmetic concerns. Although these goals are usually achieved, there are still occasional unexpected results, such as reexcision of the tumor due to a positive margin assessment, tumor local recurrence, unsatisfactory cosmetic results, and breastpain. Other than surgical experience and judgment, there are currently no toolswhich can predict the outcome of partial mastectomy on the contour and deformity of the treated breast. The objective of this dissertation is to propose computational framework, which contributes to BCT operations, this was achieve by exploring two areas.On the one hand we developed a multiscale model adapted for breast cancer tumor growth, ductal carcinoma in situ (DCIS). The model features included: nutrients growth limitation, wall degradation enzyme and HER2 chemical expression tumor phenotype. Our model successfully simulate some pattern of DCIS carcinoma.Among the interesting result we showed that the enzyme contributed to a greater tumor size and that when HER2 was over expressed, the growth limiting factor wasthe EGFR. On the other hand, we developed a virtual surgery box to simulate BCT surgery. The box will input MRI patient data and will output cosmetic and functional indicator to rate the impact of the surgery. It appears that stiffness of the tissue, resection radius as well as the lump quadrant location are the most sensitive parameters to the indicators. A healing model was also embedded to simulate the wound closure after resection, this model was stress dependent and illustrate anasymmetric wound closure progression.The tools developed in this research allows a new type of field convergence between the surgery and computation field. At the local level it will allow surgeons and patient to be able to communicate on the pertinence and necessity of performing alumpectomy surgery, enabling to anticipate the possible outcome of the operation.On the global aspect this type of tool gives birth to a new type of field: computational surgery, where computer scientist and surgeons work hand in hand to provide the best and the most reliable service to the patients

APA, Harvard, Vancouver, ISO, and other styles

7

Donaghy, Kathleen B. "Biopsychosocial factors in breast cancer." Virtual Press, 1997. http://liblink.bsu.edu/uhtbin/catkey/1115723.

Full text

Abstract:

In the treatment of early stage breast cancer, both mastectomy and lumpectomy followed by radiation therapy have been recognized as having similar survival rates. Increasingly, women are being given the opportunity to choose which of these surgical treatment options they wish to pursue. Decisions tend to be made rather quickly, and some women may later regret their treatment choice. In this study, an instrument (Breast Cancer Treatment Inventory (BCTI)) was developed that identified five primary sources of influence that affect women's breast cancer treatment decisions: cosmetic outcome, preparedness, physician's choice, short-term effects, and long-term effects. Items were generated and refined by oncology professionals and breast cancer survivors, followed by a pilot study conducted with members of a breast cancer support group. The resulting 28-item scale was completed by 139 early stage breast cancer patients. A series of oblique factor analyses yielded a five-factor solution with reliabilities ranging from .66 - .87. Content validity was enhanced by involving oncology experts and women with breast cancer in the item generation procedures. Use of the BCTI may assist women through a methodical and effective decision-making process. The BCTI may also be appropriate for research studiesinvolving the process and prediction of treatment selection since it meets requirements for ease of administration, brevity, reliability, and validity.
Department of Counseling Psychology and Guidance Services

APA, Harvard, Vancouver, ISO, and other styles

8

Fleischer, Anne. "Exploratory study of breast cancer survivors' lived experience : activity engagement during and after breast cancer treatment." Diss., NSUWorks, 2015. https://nsuworks.nova.edu/hpd_ot_student_dissertations/34.

Full text

Abstract:

The aim of this study is to describe breast cancer survivors' experiences and the associated meanings participating in their important activities during and after breast cancer treatment and the relationship among the survivor, environment, occupation, and performance, using a concurrent mixed method design. Ten survivors between the ages of 45 and 64 with Stage I, II, or III breast cancer who had been treated consecutively with surgery, chemotherapy, and radiation therapy were recruited for the study. Each survivor completed the Activity Card Sort-modified scoring system (ACSm) during the first and last week of radiation therapy and 3 and 6 months post radiation therapy. Additionally, each survivor participated in a semi-structured interview at the end of radiation therapy and 6 months afterwards. Qualitative data was analyzed using interpretative phenomenological analysis (IPA) to understand the survivors' experiences participating in their most important activities. The means and standard deviations of the proportion of activities resumed for the participants' global and category activities were calculated at each time point. A desire to resume participation in meaningful activities emerged from the data and demonstrated the interrelationship between environment, person, and occupation. Themes from the last week of radiation were (a) individual outlook influences how activities are approached, (b) social support reduces the stress of life, (c) side effects influence how activities are completed, and (d) personal and treatment stresses and struggles influenced their perspectives on life. At 6 months post radiation therapy, the themes were (a) emotional effect on activities, (b) life after cancer has changed due to cancer diagnosis and treatment, and (c) side effects continue to influence daily activities. Using the seven stages of analyzing mixed method data developed by Onwuegbuzie and Teddlie (2003), the qualitative and quantitative data were integrated. The results illustrated that the participants resumed a greater proportion of instrumental activities, which were reported consistently as one of their five most important activities. Additionally, supportive extrinsic factors appeared to be more influential in resuming participation important activities than intrinsic factors. Findings from this study support using the Person-Environment-Occupational-Performance (PEOP) model to develop treatment plans for women undergoing or recovering from breast cancer treatment.

APA, Harvard, Vancouver, ISO, and other styles

9

Molenaar, Jacobus. "Treatment decision support for early breast cancer patients." [S.l. : Amsterdam : s.n.] ; Universiteit van Amsterdam [Host], 2004. http://dare.uva.nl/document/77496.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Smoot, Betty. "Upper extremity function following treatment for breast cancer." Diss., Search in ProQuest Dissertations & Theses. UC Only, 2009. http://gateway.proquest.com/openurl?url_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:dissertation&res_dat=xri:pqdiss&rft_dat=xri:pqdiss:3359582.

Full text

APA, Harvard, Vancouver, ISO, and other styles

More sources

Books on the topic "Breast cancer treatment][Cancer"

1

Vaidya, Jayant S. Breast cancer. Oxford: Health Press, 2010.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

2

Breast cancer. New York: Demos Medical, 2010.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

3

Breast cancer. New York: Springer, 1999.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

4

Breast cancer treatment options. Commack, N.Y: Nova Science Publishers, 1999.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

5

J, Thomas Jeremy St, and Dixon, J. M. (J. Michael), eds. Breast cancer. Oxford: Clinical Pub., 2012.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

6

Dixon, J. M. Understanding breast cancer. Poole: Family Doctor in association with the British Medical Association, 2010.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

7

Necula, Virgil. Breast cancer: Women's killer. West Conshohocken, PA: Infinity Pub., 2008.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

8

Kneece, Judy C. Your breast cancer treatment handbook. 2nd ed. Columbia, South Carolina: EduCare Pub., 1996.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

9

Toi, Masakazu, Eric Winer, John Benson, and Suzanne Klimberg, eds. Personalized Treatment of Breast Cancer. Tokyo: Springer Japan, 2016. http://dx.doi.org/10.1007/978-4-431-55552-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Mina, Lida A., Anna Maria Storniolo, Hal Douglas Kipfer, Cindy Hunter, and Kandice K. Ludwig. Breast Cancer Prevention and Treatment. Cham: Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-19437-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

More sources

Book chapters on the topic "Breast cancer treatment][Cancer"

1

Wilding, G., and M. E. Lippman. "Breast Cancer." In New Directions in Cancer Treatment, 463–67. Berlin, Heidelberg: Springer Berlin Heidelberg, 1989. http://dx.doi.org/10.1007/978-3-642-83405-9_26.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Veronesi, Umberto. "Treatment: General Strategy." In Breast Cancer, 40–41. Berlin, Heidelberg: Springer Berlin Heidelberg, 1990. http://dx.doi.org/10.1007/978-3-642-76054-9_5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Karanlik, Hasan, and Abdullah Igci. "In Situ Cancer Treatment." In Breast Cancer, 303–10. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-96947-3_12.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

White, Julia, Michael C. Joiner, and Liyi Xie. "Breast Cancer." In ALERT • Adverse Late Effects of Cancer Treatment, 227–53. Berlin, Heidelberg: Springer Berlin Heidelberg, 2013. http://dx.doi.org/10.1007/978-3-540-75863-1_10.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Veronesi, Umberto. "Treatment of Overt Metastatic Disease." In Breast Cancer, 56–61. Berlin, Heidelberg: Springer Berlin Heidelberg, 1990. http://dx.doi.org/10.1007/978-3-642-76054-9_9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Ak, Naziye, and Adnan Aydiner. "Systemic Treatment Drugs and Regimens." In Breast Cancer, 587–608. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-96947-3_27.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Pierquin, B., and L. Grimard. "Radiation Therapy as Primary Treatment." In Breast Cancer, 169–80. Berlin, Heidelberg: Springer Berlin Heidelberg, 1989. http://dx.doi.org/10.1007/978-3-642-83675-6_12.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Andre, Rosario, Simona Ruxandra Volovat, and Fatima Cardoso. "Treatment of Advanced Disease: Guidelines." In Breast Cancer, 549–56. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-48848-6_44.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Harms, Steven E. "Breast MR for Treatment Planning." In Breast Cancer, 155–83. New York, NY: Springer New York, 2013. http://dx.doi.org/10.1007/978-1-4614-8063-1_8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Dellapasqua, Silvia. "Systemic Treatment for Specific Medical Situations." In Breast Cancer, 599–607. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-48848-6_49.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Breast cancer treatment][Cancer"

1

Lins, Alane F., Geovana C. Silva, Guilherme de A. Rodrigues, Isabela C. Moreira, Lucas F. A. Mendonça, Leticia L. C. Real, and Luiza S. Coutinho. "IMPLICATIONS OF ALTERNATIVE TREATMENT IN BREAST CANCER." In Brazilian Breast Cancer Symposium. v29s1, 2019. http://dx.doi.org/10.29289/259453942019v29s1ep36.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Sztejnberg, Manuel L., and Tatjana Jevremovic. "Advanced Application of BNCT in Advanced Cancers." In 17th International Conference on Nuclear Engineering. ASMEDC, 2009. http://dx.doi.org/10.1115/icone17-75906.

Full text

Abstract:

We present a new concept of one form of radiation binary targeted therapy that may offer hope for the often fatal relapsed and/or metastasized HER2+ cancers. The idea is to deliver boronated (boron-10 isotope) anti-HER2 monoclonal antibodies (mAbs) to the patient to be deposited preferentially into the tumor followed by one session of a low energy neutron irradiation. Based on actual computed tomography data, we present the comprehensive theoretical (numerical) modeling of the new approach in designing the treatment conditions for the boron neutron capture therapy (BNCT) using the MITRII-FCB neutron beam facility. The results show the effectiveness of the proposed treatment option for the advanced breast cancers and the metastasized breast cancers in the lungs of a patient. Our theoretical analysis concludes that with a boron concentration of ∼316 μg/g in tumor and a tumor-to-healthy tissue boron concentration ratio of 35:1, this new BNCT breast cancer treatment can be performed with very low doses to normal tissue and 50 Gy, or higher, doses delivered to the tumor regions. In particular, when applied to the breast cancer treatment, the resulting doses to skin and lung remain under the tolerance dose values. We also went beyond the traditional application of the BNCT and analyzed its applicability in targeting the metastasized breast cancer; using the same theoretical approach we determined the doses delivered into the patient lung with scattered cancer loci.

APA, Harvard, Vancouver, ISO, and other styles

3

Sivasankaran, Nivetha. "Biosensor and breast cancer treatment." In 2015 International Conference on Robotics, Automation, Control and Embedded Systems (RACE). IEEE, 2015. http://dx.doi.org/10.1109/race.2015.7097239.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Caetano, Júlia J., Daniel B. Sousa, Leonora S. F. Couto, Paula O. C. Queiroz, and Bruna E. Miranda. "ACCESSIBILITY TO BREAST CANCER TREATMENT AND BARRIERS TO HEALTH ASSISTANCE." In Brazilian Breast Cancer Symposium. v29s1, 2019. http://dx.doi.org/10.29289/259453942019v29s1ep33.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Rocha, Marina E., Maria Clara Santos Camargos, Tainara Neres Souza de Jesus, and Lorena T. Quirino. "NURSING ASSISTANCE IN THE TREATMENT OF BREAST CANCER TO VULNERABILITIES AND CHALLENGES." In Brazilian Breast Cancer Symposium. v29s1, 2019. http://dx.doi.org/10.29289/259453942019v29s1ep56.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Franca, Flávia C., Idam de Oliveira Junior, Marco A. de Lima, and René A. C. Vieira. "GEOMETRIC COMPENSATION TECHNIQUE FOR BREAST CONSERVATIVE TREATMENT: EXPANDING THE INDICATIONS AND COSMETIC EVALUATION." In Brazilian Breast Cancer Symposium. v29s1, 2019. http://dx.doi.org/10.29289/259453942019v29s1cp04.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Vieira, René A. C., Igor A. Silva, Fabiola C. B. Silva, Antônio Bailão Junior, Idam de Oliveira Junior, Almir J. Sarri, Jonathas J. Silva, and Carlos E. Paiva. "ONCOPLASTIC SURGERY IN BREASTCONSERVATIVE TREATMENT: PATIENT PROFILE AND IMPACT ON QUALITY OF LIFE." In Brazilian Breast Cancer Symposium. v29s1, 2019. http://dx.doi.org/10.29289/259453942019v29s1g09.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Stearns, V. "ES1-3: Treatment of Metastatic Breast Cancer – Breast Cancer as a Chronic Disease: Triple Negative Breast Cancer." In Abstracts: Thirty-Fourth Annual CTRC‐AACR San Antonio Breast Cancer Symposium‐‐ Dec 6‐10, 2011; San Antonio, TX. American Association for Cancer Research, 2011. http://dx.doi.org/10.1158/0008-5472.sabcs11-es1-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Yagi, Nathalya A., Nilceana M. A. Freitas, Thais F. Simionatto, Sylvia S. Pires, Mattheus H. Vale, Jean T. Paiva, Edesio Martins, and Ruffo Freitas Junior. "OVERALL SURVIVAL INCREASE AFTER TREATMENT OF BRAIN METASTASIS FOR HER-2 POSITIVE PATIENTS USING TRASTUZUMAB." In Brazilian Breast Cancer Symposium. v29s1, 2019. http://dx.doi.org/10.29289/259453942019v29s1cp07.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Mendonça, Natália S. D., Guilherme A. Sampaio, Laine R. Martins, Júlia de J. Caetano, Murilo Henrique Costa e. Silva, and Juliana A. Sampaio. "THE RELATIONSHIP BETWEEN PHYSICAL ACTIVITY AND BREAST CANCER: PREVENTION, TREATMENT AND RECONSTRUCTION OF SELF-ESTEEM." In Brazilian Breast Cancer Symposium. v29s1, 2019. http://dx.doi.org/10.29289/259453942019v29s1ep32.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Breast cancer treatment][Cancer"

1

Markovic, Dubravka, and Edward P. Cohen. Treatment of Breast Cancer with Immunogenic Cells Transfected with DNA from Breast Cancer Cells. Fort Belvoir, VA: Defense Technical Information Center, July 2001. http://dx.doi.org/10.21236/ada396744.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Adamson, Eileen D. Cripto: A Target for Breast Cancer Treatment. Fort Belvoir, VA: Defense Technical Information Center, June 2005. http://dx.doi.org/10.21236/ada438430.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

McClellan, Mark B. Breast Cancer: Treatment, Outcomes, and Cost-Effectiveness. Fort Belvoir, VA: Defense Technical Information Center, June 2000. http://dx.doi.org/10.21236/ada398496.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Adamson, Eileen D. Cripto: A Target for Breast Cancer Treatment. Fort Belvoir, VA: Defense Technical Information Center, June 2003. http://dx.doi.org/10.21236/ada418017.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Deisseroth, Albert B. Vectors for Treatment of Metastatic Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, August 2005. http://dx.doi.org/10.21236/ada448903.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Adamson, Eileen D. Cripto: A Target for Breast Cancer Treatment. Fort Belvoir, VA: Defense Technical Information Center, June 2002. http://dx.doi.org/10.21236/ada407397.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Adamson, Eileen D. Cripto: A Target for Breast Cancer Treatment. Fort Belvoir, VA: Defense Technical Information Center, June 2004. http://dx.doi.org/10.21236/ada427946.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Deisseroth, Albert B. Vectors for Treatment of Metastatic Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, August 2004. http://dx.doi.org/10.21236/ada429189.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Reich, Norbert R. An Epigenetic Approach to Breast Cancer Treatment. Fort Belvoir, VA: Defense Technical Information Center, August 2003. http://dx.doi.org/10.21236/ada429260.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Deisseroth, Albert B. Vectors for Treatment of Metastatic Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, August 2006. http://dx.doi.org/10.21236/ada463416.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!